Research and Markets (http://www.researchandmarkets.com/research/kfpmft/recurrent) has announced the addition of the "Recurrent Malignant Glioma-Pipeline Insights, 2016" report to their offering.
Recurrent Malignant Glioma-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Recurrent Malignant Glioma. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Recurrent Malignant Glioma.
The report also assesses the Recurrent Malignant Glioma therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.
Scope
- The report provides competitive pipeline landscape of Recurrent Malignant Glioma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Key Topics Covered:
- Recurrent Malignant Glioma Overview
- Recurrent Malignant Glioma Pipeline Therapeutics
- Recurrent Malignant Glioma Therapeutics under Development by Companies
- Recurrent Malignant Glioma Filed and Phase III Products
- Comparative Analysis
- Recurrent Malignant Glioma Phase II Products
- Comparative Analysis
- Recurrent Malignant Glioma Phase I and IND Filed Products
- Comparative Analysis
- Recurrent Malignant Glioma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Recurrent Malignant Glioma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Recurrent Malignant Glioma - Discontinued Products
- Recurrent Malignant Glioma - Dormant Products
- Companies Involved in Therapeutics Development for Recurrent Malignant Glioma
For more information visit http://www.researchandmarkets.com/research/kfpmft/recurrent
View source version on businesswire.com: http://www.businesswire.com/news/home/20160119006044/en/